Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
Type:
Grant
Filed:
April 28, 2014
Date of Patent:
June 30, 2015
Assignee:
EVEREST BIOSCIENCES, INC.
Inventors:
Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
Type:
Application
Filed:
April 28, 2014
Publication date:
August 21, 2014
Applicant:
Everest Biosciences, Inc.
Inventors:
Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson
Abstract: The disclosure describes compounds of formula I, wherein the wedged bonds, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, X and Y have meanings given in the description, and pharmaceutically-acceptable salts thereof; and methods of using such compounds useful in the treatment of cancer and conditions affected by inhibition of angiogenesis. Also provided, are processes for the preparation of formula I, by reacting formula I with other compounds; and processes for the preparation of a pharmaceutical formulation by bringing into association, a compound of formula I, with therapeutic agents and/or a pharmaceutically-acceptable adjuvant, diluent, or carrier.
Type:
Grant
Filed:
March 19, 2010
Date of Patent:
June 17, 2014
Assignee:
Everest Biosciences, Inc.
Inventors:
Jenny Persson, Rikard Larsson, Olov Sterner, Martin Johansson